Taiwanese researchers have elucidated the signaling mechanism downstream of IL-17 receptor B and shown that its blockade using a neutralizing antibody reduced pancreatic cancer tumorigenesis and metastasis, while prolonging the life of tumor-bearing mice.

Days after taking the unusual step, for a Chinese company, of terminating a couple of clinical programs, Bio-Thera Solutions Ltd. said it still plans to continue R&D in antibody-drug conjugates, but with a new technology platform, the company told BioWorld.